Table 1.
Basic demographic characteristic of the study
| Parameters | Cases (n/%) |
|---|---|
| Age (y) | |
| < 60 | 81 (69.23) |
| ≥ 60 | 36 (30.67) |
| Sex | |
| Male | 77 (65.81) |
| Female | 40 (34.19) |
| Tumor location | |
| Right | 33 (28.21) |
| Left | 84 (71.79) |
| Tumor morphology | |
| Ulcerated type | 57 (48.72) |
| Protruded type | 21 (17.95) |
| Mixed type | 6 (5.13) |
| Unknown | 33 (28.21) |
| Histological differentiation | |
| Well + moderate | 92 (78.63) |
| Poor | 25 (21.37) |
| Mucinous element | |
| With | 18 (15.39) |
| Without | 99 (84.61) |
| Combined T stages | |
| T1 + T2 + T3 | 94 (80.34) |
| T4 | 23 (19.66) |
| Combined N stages | |
| N0 | 30 (25.64) |
| N1+N2 | 87 (74.32) |
| TNM stages | |
| II | 30 (25.64) |
| III | 87 (74.32) |
| Tumor deposits | |
| With | 20 (17.09) |
| Without | 97 (82.91) |
| RAS mutation | |
| Mutated | 6 (5.13) |
| Wild-type | 11 (9.40) |
| Unknown | 100 (85.47) |
| MSS status | |
| MSI-H | 3 (2.56) |
| MSI-L + MSS | 66 (56.41) |
| Unknown | 48 (41.03) |
| Ki-67 percentage | |
| ≥ 75% | 41 (35.04) |
| 50–75% | 14 (11.97) |
| 0–50% | 7 (5.98) |
| Unknown | 55 (47.01) |
| Risk factors | |
| None | 58 (49.57) |
| 1 | 34 (29.06) |
| 2 | 15 (12.82) |
| 3 | 9 (7.69) |
| 4 | 1 (0.86) |
| Adjuvant therapy regimens | |
| XELOX | 71 (60.83) |
| FOLFOX | 11 (9.40) |
| XELOX + X | 17 (14.53) |
| FOLFOX + X | 1 (0.85) |
| XELOX + FOLFOX | 8 (6.84) |
| X | 1 (0.85) |
| Others | 8 (6.70) |